宜安科技(300328.SZ):4名董高大宗交易減持合計290萬股
格隆匯5月27日丨宜安科技(300328.SZ)公佈,公司收到公司董事兼總經理楊潔丹、董事兼副總經理張春聯及董事、副總經理兼生產總監湯鐵裝、副總經理兼技術總監李衞榮各自出具的《股份減持吿知函》,因個人資金需求,楊潔丹、張春聯、湯鐵裝及李衞榮於2022年5月26日通過深圳證券交易所大宗交易系統分別減持其持有的公司無限售條件股份為80萬股、50萬股、80萬股及80萬股,分別佔公司總股本的0.12%、0.07%、0.12%及0.12%。上述四名董事、高級管理人員合計減持持有的公司無限售條件股份為290萬股,佔公司總股本的0.42%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.